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Abstract 
TDP-43 and α-synuclein are two disease proteins involved in a wide range of neurodegen-
erative diseases. While TDP-43 proteinopathy is considered a pathologic hallmark of sporadic 
amyotrophic lateral sclerosis and frontotemporal lobe degeneration, α-synuclein is a major 
component of Lewy body characteristic of Parkinson’s disease. Intriguingly, TDP-43 protei-
nopathy also coexists with Lewy body and with synucleinopathy in certain disease conditions. 
Here we reported the effects of TDP-43 on α-synuclein neurotoxicity in transgenic mice. 
Overexpression of mutant TDP-43 (M337V substitution) in mice caused early death in 
transgenic founders, but overexpression of normal TDP-43 only induced a moderate loss of 
cortical neurons in the transgenic mice at advanced ages. Interestingly, concomitant over-
expression of normal TDP-43 and mutant α-synuclein caused a more severe loss of dopa-
minergic neurons in the double transgenic mice as compared to single-gene transgenic mice. 
TDP-43 potentiated α-synuclein toxicity to dopaminergic neurons in living animals. Our 
finding provides in vivo evidence suggesting that disease proteins such as TDP-43 and 
α-synuclein may play a synergistic role in disease induction in neurodegenerative diseases. 
Key words: TDP-43; alpha-synuclein; mice; dopaminergic neuron; Parkinson’s disease; fronto-
temporal lobe degeneration, genetic model 
1. Introduction 
TAR DNA-binding protein 43 (TDP-43) is a 
conserved ribonucleoprotein with diverse functions 
as exemplified by the ability to regulate gene tran-
scription, mRNA splicing, and RNA stability (1-6). 
While its physiological functions remain to be eluci-
dated, TDP-43 translocates to the cytoplasm and 
forms ubiquitinated aggregates in neurodegenerative 
diseases including amyotrophic lateral sclerosis (ALS) 
and frontotemporal lobe degeneration (FTLD) (7-10). 
TDP-43 proteinopathy, a hallmark of sporadic ALS 
and FTLD, is also observed in the other neurodegen-
erative diseases such as Parkinson’s disease (PD) and 
Alzheimer’s disease (11-13). Neurodegenerative dis-
eases share some features in the pathogenesis and 
pathology. Most cases of the diseases are sporadic and 
only a small proportion of them have a clear genetic 
cause. A neurodegenerative disease is characterized 
by a selected group of neurons preferably affected at 
early disease stages, but it often affects a wide range 
of different neurons at advanced disease stages. For 
example, heterogeneous neuropathology is observed 
in sporadic ALS at advanced disease stages (14-16), 
although motor neurons are preferably affected in the 
disease at early disease stages. TDP-43 proteinopathy 
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is direct evidence supporting that neurodegenerative 
diseases may be pathogenically interrelated. 
While mutation in TDP-43 is linked to ALS and 
FTLD (17-21), mutation of the α-synuclein gene is as-
sociated with PD (22-26). Overexpression of TDP-43 
with or without pathogenic mutation causes a broad 
neurodegeneration in rodents (27-32), suggesting that 
normal TDP-43 of elevated expression is neurotoxic. 
Overexpression of TDP-43 in the substantia nigra in-
duces dopaminergic neuron death (33), suggesting 
that TDP-43 neurotoxicity is not restricted to the 
neurons preferably affected in ALS and FTLD. Over-
expression of pathogenically mutated α-synuclein 
causes dopaminergic neuron death in transgenic mice 
at advanced ages (34). Neurodegenerative diseases 
are commonly thought of multifactorial pathogenesis. 
To test this hypothesis, we examined whether TDP-43 
potentiates α-synuclein toxicity to dopaminergic 
neurons in transgenic mice. Transgenic overexpres-
sion of the normal TDP-43 caused a significant loss of 
neurons in the frontal cortex, but not in the substantia 
nigra pars compacta (SNpc). When normal TDP-43 
and mutant α-synuclein were overexpressed simul-
taneously in the dopaminergic neurons, a dramatic 
loss of the neurons was detected in the SNpc of 
transgenic mice. Our results suggest that neurotoxic 
factors such as TDP-43 and α-synuclein may play a 
synergistic role in the pathogenesis of neurodegener-
ative diseases. 
2. Materials and Methods 
Animal experiments 
Animal use followed NIH guidelines and the 
animal use protocol was approved by the Institutional 
Animal Care and Use Committees at Thomas Jeffer-
son University. As described in our publication (32, 
35), the cDNA of normal human TDP-43 and its mu-
tant form (M337V substitution) was created by PCR 
and was cloned into CAG expression vector. Linear-
ized transgene constructs were injected into the pro-
nuclei of fertilized eggs of C57BL/6J mice. Transgenic 
mice were identified by PCR amplification of the 
human TDP-43 transgene with the following primers: 
5’-TGCGGGAGTTCTTCTCTCAG-3’ (forward) and 
5’-AGCCACCTGGATTACCACCA-3’ (reverse). Du-
al-mutant α-synuclein transgenic mice were received 
from Dr. Richfield and were genotyped by PCR anal-
ysis as described in the original publications (34, 36). 
All transgenic mice were maintained on C57BL6 ge-
nomic background. 
Mouse psychomotor activity was measured by 
Rotarod test as described previously (35, 37). Mice 
were tested on a rotating Rotarod (Med Associates) 
twice a week since three months of age. On a testing 
day, a mouse was tested three times separated by 10 
minutes of rest and was allowed to run on a rotating 
Rotarod with accelerated speeds for a maximal period 
of five minutes. The average time of three tests was 
calculated as the latency to fall from rotating rotarod. 
Immunoblotting 
Mouse tissues were homogenized in RAPI buffer 
supplied with protease inhibitors (Promega). Tissue 
lysates were cleared by centrifugation and proteins in 
cleared lysates were measured by BCA assay (Pierce). 
Total proteins of 25 µg in each lysate were separated 
on 10% SDS-PAGE and were blotted onto PVDF 
membrane. The immunoreactivity of both human and 
mouse TDP-43 was detected with a polyclonal anti-
body (1: 500; Proteintech) and the immunoreactivity 
of human TDP-43 was detected with a mouse mono-
clonal antibody (1: 1000; Abnova, 2E2-D3). Compara-
ble loading of total proteins among samples was es-
timated by probing the same membranes with a 
mouse monoclonal antibody recognizing mouse 
glyceraldehyde-3-phosphatedehydrogenase (1: 2000; 
Abnova). Immunoreactivity was visualized by ECL 
reaction (Pierce). 
Toluidine blue staining 
As described in our publication (32), the ventral 
and dorsal nerve roots of TDP-43 transgenic mice 
were examined for axon degeneration by toluidine 
blue staining. Mice were anesthetized and perfused 
with a mixture of 4% PFA and 2% glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4). The L4 ventral and 
dorsal roots were removed and post-fixed in the same 
fixative at 4°C overnight. The roots were further fixed 
in 1% osmium tetroxide in 0.1 M phosphate buffer 
(pH 7.4) for 1 h. The well-fixed tissues were dehy-
drated in graded ethanol and were embedded in Epon 
812 (Electron Microscopic Sciences, Fort Washington, 
PA). Nerve roots were transversely cut into 1 
µm-thick sections. Axons in the nerve roots were 
examined in the semi-thin sections under a light mi-
croscope (Nikon 80i). 
Immunostaining and histology 
Mouse tissues were fixed in 4% PFA and were 
cryopreserved in 30% sucrose. On a Cryostat, mouse 
brain was cut into coronal sections of 20 µm and 
mouse spinal cord was cut into traverse sections of 15 
µm. Human TDP-43 immunoreactivity was detected 
by incubating tissue sections with a monoclonal an-
tibody specific for human TDP-43 (1: 500; Abnova, 
2E2-D3) and was visualized using an ABC kit in 
combination with diaminobenzidine (Vector). Im-
munostained sections were lightly counterstained 
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with hematoxylin to display the nuclei. Dou-
ble-labeling immunofluorescence staining was per-
formed as described previously (32). The following 
antibodies were used for immunofluorescence stain-
ing: mouse monoclonal antibody to human TDP-43 (1: 
500; Abnova, 2E2-D3), chicken antibody to ubiquitin 
(1: 1000; Sigma), rabbit antibody to tyrosine hydrox-
ylase (TH; Pel-Freez; 1:1000), and mouse monoclonal 
antibody to human α-synuclein (1: 1000; Abcam, 
4B12). Frozen sections of the gastrocnemius muscle 
were stained with hematoxylin and eosin (H&E) to 
display tissue structures. 
Stereological cell counting 
As described in our publication (38), the number 
of dopaminergic neurons in the SNpc was estimated 
by stereological cell counting. PFA-fixed mouse mid-
brain was cut on a Cryostat into four series of sections 
and every fourth section was immunostained for TH. 
The number of TH-positive neurons in the SNpc was 
estimated with fractionator-based stereology software 
(Stereologer), which was run on a PC computer at-
tached to a Nikon 80i microscope with a motorized 
XYZ stage (Prior). The number of cortical neurons in 
the frontal cortex was also estimated by stereological 
cell counting as described previously (39). 
3. Results 
Overexpression of a mutant TDP-43 causes early 
death in transgenic founders 
To develop a genetic animal model for 
TDP-43-linked ALS and FTLD, we created transgenic 
mice expressing the human TDP-43 with or without a 
pathogenic mutation (Fig. 1).  
 
 
Figure 1: Expression of human TDP-43 in transgenic mice. a, Schematic shows the structure of human TDP-43 
transgene. The transgene constructs consist of the CAG promoter, the first noncoding exon and the first intron of the 
chicken beta actin gene, the human TDP-43 cDNA with or without pathogenic mutation (M337V substitution), and the three 
repeats of SV40 polyadenylation signal. b, PCR analysis identified transgenic founders carrying the normal or the mutant 
(M337V) human TDP-43 transgene (hTDP-43). C+: positive control; C-: negative control. c, Immunoblotting detected a 
robust expression of human TDP-43 in the forebrain of transgenic founder mice. NG: nontransgenic mouse brain. d, Photo 
showing a transgenic founder mouse and its nontransgenic littermate (NG) at 7 days of age. e, Immunoblotting detected a 
robust expression of human TDP-43 in the central nerve system of normal TDP-43 transgenic mice. Each lane was loaded 
with 25 µg of total protein. The same membrane was first probed with a TDP-43 antibody recognizing both human and 
mouse TDP-43 and was then probed with a GAPDH antibody. Muscle: skeletal muscle; hippo: hippocampus. 
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The hybrid promoter CAG is shown to drive 
transgene expression robustly and ubiquitously in 
rodents (35, 40, 41), and thus it was used to drive 
TDP-43 transgenes in mice (Fig. 1a). We chose M337V 
substitution as an example of TDP-43 mutations be-
cause this mutant causes typical ALS with a mid-
dle-age onset of symptoms (18). We obtained four 
transgenic founders expressing mutant TDP-43M337V 
and one founder expressing normal TDP-43 (Fig. 1). 
These transgenic founders were born of normal sizes; 
three TDP-43M337V founders lost mobility soon after 
birth and died within 10 days of birth (Fig. 1d). One 
TDP-43M337V female founder lived to 4 months of age, 
but it was infertile and died shortly after immobility 
was observed. We examined this mutant founder for 
neuronal and axonal degeneration in the spinal cord 
and nerve roots, but did not detect a significant loss of 
spinal motor neurons or motor axons. Similar to our 
finding in transgenic rats (32), constitutive overex-
pression of mutant TDP-43 in mice caused severe 
phenotypes in transgenic founders, preventing 
transgenic lines from establishment. By contrast, the 
transgenic founder overexpressing normal TDP-43 
was healthy and fertile. 
To expand the normal TDP-43 transgenic mouse 
colony, we crossed the transgenic founder with 
C57BL6/J mice newly purchased from Jackson La-
boratories. Unexpectedly, some male transgenic mice 
of the first three generations died within a week after 
immobility was observed. No detectable phenotype 
was observed in TDP-43 transgenic mice beyond the 
fourth generation. We examined the sick mice and did 
not detect a degeneration of spinal motor neurons or 
motor axons. The copy number of human TDP-43 
transgene was unaltered through mouse generations 
examined (all 22 copies). We maintained a C57BL6 
colony derived from a mating pair that was pur-
chased from the Jackson Laboratories four years ago, 
and we created TDP-43 transgenic mice on the ge-
nomic background of this mouse colony. The genomic 
background of TDP-43 transgenic mice could thus be 
considered congenic, but unidentified environmental 
or genetic factors may alter phenotypic expression in 
our TDP-43 transgenic mice. 
Overexpression of the normal TDP-43 causes 
cortical neuron degeneration in transgenic mice 
TDP-43-positive inclusion is a hallmark of spo-
radic ALS and FTLD (42, 43), suggesting that TDP-43 
may be involved in the pathogenesis of the sporadic 
diseases. We used TDP-43 transgenic mice of the sixth 
generation for the following experiments. A robust 
expression of human TDP-43 was detected in the 
brain, spinal cord, and skeletal muscles of TDP-43 
transgenic mice (Figs. 1e, 2b, 3b, and 3c), but not in the 
tissues of nontransgenic controls (Figs. 2a and 3a). On 
a homogenous genomic background, TDP-43 trans-
genic mice did not develop abnormality in psycho-
motor activity by age of one year (Fig. 2c). Accord-
ingly, TDP-43 transgenic mice did not develop de-
tectable pathology in the spinal motor neurons (Fig. 
2d-2e), in the dorsal and ventral nerve roots (Fig. 
2f-2i), and in the skeletal muscles (Fig. 2j-2k). Muta-
tion of TDP-43 is also linked to FTLD (44). Altered 
expression of normal TDP-43 may affect cortical neu-
rons in transgenic animals (32). We assessed cortical 
and hippocampal neurons by an unbiased meth-
od—stereological cell counting and detected a signif-
icant loss of cortical neurons in the transgenic mice at 
advanced ages (Fig. 3d-3i). Ubiquitinated TDP-43 ag-
gregates are common to sporadic ALS and FTLD (42, 
43). We examined these pathologies in TDP-43 trans-
genic mice, but did not detect typical TDP-43 or 
ubiquitin aggregates in the brain and spinal cord of 
the aged mice (Fig. 4a-4l). Consistent with our find-
ings in TDP-43 transgenic rats (32), ubiquitin and 
TDP-43 aggregation is not essential to neuronal death. 
Overexpression of normal TDP-43 potentiates 
alpha-synuclein toxicity to dopaminergic neurons 
in transgenic mice 
TDP-43 proteinopathy is observed in a wide 
range of neurodegenerative diseases including PD 
(12, 13). Transient overexpression of TDP-43 in the 
substantia nigra causes dopaminergic neuron death 
(33). Alpha-synuclein is a major component of Lewy 
body characteristic of PD and pathogenic mutation of 
α-synuclein is implicated in PD pathogenesis (22-26). 
We further examined whether TDP-43 modifies 
α-synuclein toxicity in the double transgenic mice. In 
TDP-43 transgenic mice, a substantial number of do-
paminergic neurons expressed human TDP-43 as 
shown by double-labeling immunofluorescence 
staining (Fig. 5a-5f). Overexpression of human 
TDP-43 alone did not induce a significant loss of do-
paminergic neurons in the transgenic mice (Fig. 5q). 
We then crossed TDP-43 transgene onto a mutant 
α-synuclein transgenic background (Fig. 5g-5l). Pre-
vious study showed that overexpression of mutant 
α-synuclein causes a significant loss of dopaminergic 
neurons in male mice at advanced ages (34); however, 
we did not detect a significant loss of dopaminergic 
neurons in the mutant α-synuclein transgenic mice 
though a trend of neuronal loss was observed (Fig. 
5q). Our result does not contradict the previous study 
because we examined three male and three female 
α-synuclein transgenic mice. Male mice appeared 
more sensitive to mutant α-synuclein toxicity than 
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female mice. In our study, statistical significance 
might be obscured by a limited number of animals 
and a mixture of male and female mice. Interestingly, 
simultaneous overexpression of normal TDP-43 and 
mutant α-synuclein caused a significant loss of do-
paminergic neurons in the transgenic mice as com-
pared to either single transgenic control (Fig. 5m-5q), 
suggesting that TDP-43 potentiated α-synuclein neu-
rotoxicity. 
 
 
 
 
Figure 2: No detectable impairment in the motor system of TDP-43 transgenic mice at advanced ages. a, b, 
Immunostaining detected human TDP-43 only in the TDP-43 transgenic mouse (hTDP43), but not in its nontransgenic 
control (NT). Cross sections of lumbar spinal cord were immunostained with a monoclonal antibody recognizing human 
TDP-43 and the ventral horns of lumbar cords were photographed. c, Rotarod test revealed no difference in psychomotor 
activity between the TDP-43 transgenic mice (hTDP43) and the nontransgenic littermates (NT). Each group consisted of 8 
mice with equal sex composition. d, e, Cresyl violet staining revealed no significant loss of motor neurons in the  lumbar 
cords of TDP-43 transgenic mice. f-i, Toluidine blue staining showed the structure of the L4 ventral roots (f, g) and the L4 
dorsal roots (h, i) in TDP-43 transgenic mice and their nontransgenic littermates at the age of 11 months. j, k, H&E staining 
revealed no atrophy of skeletal muscles in the TDP-43 transgenic mice. Scale bars: a-b and f-k, 20 µm; d-e, 50 µm. 
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Figure 3: A significant loss of cortical neurons in the frontal cortex of TDP-43 transgenic mice at advanced 
ages. a-c, Immunostaining revealed a robust expression of human TDP-43 in the cortex and dentate gyrus of TDP-43 
transgenic mouse, but not in the cortex of a nontransgenic control (NT). d-g, Cresyl violet staining showed the neurons in 
the frontal cortex (d, e) and hippocampus (f, g). Scale bars: a-e, 20 µm; and f-g, 50 µm. h, i, Stereological cell counting 
revealed a significant loss of neurons in the frontal cortex, but not in the dentate gyrus, of TDP-43 transgenic mice. Mice 
were 10-12 months old. Data are means + SD (n = 5). * indicates p < 0.05. 
 
Figure 4: Ubiquitin 
inclusion unde-
tectable in TDP-43 
transgenic mice at 
advanced ages. a-l, 
Double-labeling flu-
orescence staining 
revealed no ubiquitin 
inclusion in 
TDP-43-overexpressi
ng cells in transgenic 
mice at 10 months of 
age. Tissue sections 
from TDP-43 trans-
genic mice (hTDP43) 
or the nontransgenic 
controls (NT) were 
immunostained for 
human TDP-43 and 
mouse ubiquitin. All 
scale bars: 20 µm. 
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Figure 5: Synergistic effects of TDP-43 and mutant alpha-synuclein on dopaminergic neurons in transgenic 
mice. a-f, Double-fluorescence labeling revealed a substantial expression of human TDP-43 in the dopaminergic neurons of 
human TDP-43 transgenic mice (hTDP43), but not in the neurons of nontransgenic mice (NT). Coronal sections of the 
midbrain were simultaneously immunostained for human TDP-43 and mouse tyrosine hydroxylase (TH, a marker of do-
paminergic neurons). g-l, double-labeling fluorescence staining detected a robust expression of a mutant human al-
pha-synuclein (hSYN) in the dopaminergic neurons of hSYN transgenic mice, but not in the neurons of nontransgenic mice 
(NT). m-p, Representative photos of low (m, o) or high (n, p) magnification showing dopaminergic neurons in the substantia 
nigra of TDP-43 single (m, n) and TDP-43/hSYN double (o, p) transgenic mice. Scale bars: a-l, n and p, 20 µm; m, o, 80 µm. 
q, Stereological cell counting revealed a significant loss of dopaminergic neurons (TH-positive) in the TDP-43 and al-
pha-synuclein double transgenic mice (SYN/TDP) as compared to nontransgenic (NT) or the single transgenic (hTDP or 
SYN) mice at 10-12 months of age. Data are means + SD (n = 4-6). The symbol * indicates p < 0.05 as compared to SYN or 
hTDP transgenic mice. 
 
 
4. Discussion 
Consistent with our findings in transgenic rats 
(32), pathogenically mutated TDP-43 exhibited higher 
toxicity than the wildtype form when overexpressed 
in transgenic mice. Normal TDP-43 of elevated ex-
pression was sufficient to induce neurotoxicity in vivo. 
Moreover, TDP-43 and mutant α-synuclein synergis-
tically induced neurotoxicity when concomitantly 
overexpressed in the dopaminergic neurons of trans-
genic mice, suggesting that neuron death is a con-
vergent outcome of the toxicity of disease factors in 
neurodegenerative diseases such as PD. 
While the nature of pathogenic mutation in 
TDP-43 remains largely unknown, TDP-43 with 
pathogenic mutation or elevated expression is neu-
rotoxic in vitro and in vivo (28, 45-48). Pathogenic 
mutation of TDP-43 may cause a gain of function, a 
loss of function, or a dominant negative effect. The 
information available is not sufficient to determine the 
nature of TDP-43 mutation. Silencing of TDP-43 ex-
pression by RNAi induces neuronal death in culture 
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(49, 50). Deletion of TDP-43 causes a defect at the 
neuromuscular junction in Drosophila melanogaster 
(51). Constitutive or temporal deletion of TDP-43 in 
mice induces severe phenotypes (52, 53), underscor-
ing the importance of TDP-43 in cellular function. It 
remains unclear whether neurodegeneration can be 
induced by cell-specific deletion of TDP-43 in condi-
tional knockout mice. Forced overexpression of hu-
man TDP-43 in mice deregulates the expression of 
mouse endogenous TDP-43 (27). Since it is not known 
whether human TDP-43 can function properly in 
mouse tissues, addition of normal human TDP-43 to 
mouse genome may or may not enhance the functions 
of TDP-43. In addition, transgenic overexpression of 
mutant TDP-43 is unable to differentiate a gain of 
function from a dominant negative effect because 
both types of mutation can induce disease in trans-
genic animals (54-56). Although a more sophisticated 
model such as a TDP-43 knockin mouse is required 
for determining the natures of TDP-43 mutation, our 
results, along with previous findings (27, 28, 45-48, 50, 
52, 53), suggest a possible gain of function in TDP-43 
mutation. We previously showed that overexpression 
of normal TDP-43 does not induce ALS disease in 
transgenic rats (32). Consistent with our finding in 
rats, overexpression of normal TDP-43 in mice failed 
to induce ALS phenotypes. Interestingly, overexpres-
sion of normal TDP-43 caused a significant (though 
moderate) loss of cortical neurons in asymptomatic 
mice at advanced ages. It could not be ruled out that 
overexpression of normal TDP-43 may induce cortical 
neuron degeneration in aged rats. We will examine 
cortical neurons in normal TDP-43 transgenic rats at 
advanced ages in a follow-up study. 
TDP-43 and α-synuclein are involved in a wide 
range of neurodegenerative diseases. While TDP-43 
proteinopathy is considered a pathologic hallmark of 
ALS and FTLD (7-10), it also coexists with Lewy pa-
thology that is a characteristic of sporadic PD (57-59). 
Alpha-synuclein is a major component of Lewy body 
and Lewy neurites in PD (57-59). When concomitantly 
overexpressed in mice, TDP-43 and mutant 
α-synuclein synergistically induced dopaminergic 
neurodegeneration. Our finding is not unexpected as 
TDP-43 and α-synuclein proteinopathy coexist in pa-
tients with neurodegenerative diseases (57-59). Clini-
cally, synucleinopathy is more severe in the cases with 
than in the cases without TDP-43 proteinopathy (60). 
It remains unclear whether and how disease proteins 
(such as TDP-43, α-synuclein, β-amyloid, and tau) 
interact to induce degeneration of selected groups of 
neurons in patients with neurodegenerative diseases. 
Our study has provided in vivo evidence suggesting 
that disease proteins such as TDP-43 and α-synuclein 
may play a synergistic role in disease induction in 
neurodegenerative diseases. 
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